|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eba J, Shimokawa T, Nakamura K, Shibata T,
Misumi Y, Okamoto H, Yamamoto N and Ohe Y; Lung Cancer Study Group
of the Japan Clinical Oncology Group, : A Phase II/III study
comparing carboplatin and irinotecan with carboplatin and etoposide
for the treatment of elderly patients with extensive-disease
small-cell lung cancer (JCOG1201). Jpn J Clin Oncol. 45:115–118.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Misumi Y, Nishio M, Takahashi T, Ohyanagi
F, Horiike A, Murakami H, Kenmotsu H, Yamamoto N, Ishii M,
Shimokawa T, et al: A feasibility study of carboplatin plus
irinotecan treatment for elderly patients with extensive disease
small-cell lung cancer. Jpn J Clin Oncol. 44:116–121. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peleg R, Romzova M, Kogan-Zviagin I, Apte
RN and Priel E: Modification of topoisomerases in mammospheres
derived from breast cancer cell line: Clinical implications for
combined treatments with tyrosine kinase inhibitors. BMC Cancer.
14:9102014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu Y, Wang KY, Li Z, Liu YP, Izumi H,
Uramoto H, Nakayama Y, Ito K and Kohno K: Y-box binding protein 1
enhances DNA topoisomerase 1 activity and sensitivity to
camptothecin via direct interaction. J Exp Clin Cancer Res.
33:1122014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pitot HC: US pivotal studies of irinotecan
in colorectal carcinoma. Oncology (Williston Park). 12 8 Suppl
6:S48–S53. 1998.
|
|
7
|
Hind D, Tappenden P, Tumur I, Eggington S,
Sutcliffe P and Ryan A: The use of irinotecan, oxaliplatin and
raltitrexed for the treatment of advanced colorectal cancer:
Systematic review and economic evaluation. Health Technol Assess.
12:iii–ix, xi–162. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sadahiro S, Suzuki T, Tanaka A, Okada K,
Saito G and Kamijo A: A phase II trial of combined chemotherapy
with oral S-1 and 24-hour infusions of irinotecan plus bevacizumab
in patients with metastatic colorectal cancer. Oncology.
88:353–359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao J: Study on anti-tumor activity and
mechanism of novel Irinotecan derivative ZBH-1208 in vitro
(unpublished PhD thesis). Jilin University. 2015.
|
|
10
|
Yin Q, Fischer L, Noethling C and Schaefer
WR: In vitro-assessment of putative antiprogestin activities of
phytochemicals and synthetic UV absorbers in human endometrial
Ishikawa cells. Gynecol Endocrinol. 31:578–581. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Graeven U, Arnold D, Reinacher-Schick A,
Heuer T, Nusch A, Porschen R and Schmiegel W: A randomised phase II
study of irinotecan in combination with 5-FU/FA compared with
irinotecan alone as second-line treatment of patients with
metastatic colorectal carcinoma. Onkologie. 30:169–174.
2007.PubMed/NCBI
|
|
13
|
Mackenzie PI, Bock KW, Burchell B,
Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS and
Nebert DW: Nomenclature update for the mammalian UDP
glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics.
15:677–685. 2015. View Article : Google Scholar
|
|
14
|
Stewart ZA, Westfall MD and Pietenpol JA:
Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol
Sci. 24:139–145. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arellano M and Moreno S: Regulation of
CDK/cyclin complexes during the cell cycle. Int J Biochem Cell
Biol. 29:559–573. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiong Y, Hannon GJ, Zhang H, Casso D,
Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin
kinases. Nature. 366:701–704. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldstein M, Roos WP and Kaina B:
Apoptotic death induced by the cyclophosphamide analogue
mafosfamide in human lymphoblastoid cells: Contribution of DNA
replication, transcription inhibition and Chk/p53 signaling.
Toxicol Appl Pharmacol. 229:20–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen P: Research progress on tumor-related
genes. J Basic Clin Oncol. 21:90–92. 2008.(In Chinese).
|
|
19
|
Nigam N, Prasad S, George J and Shukla Y:
Lupeol induces p53 and cyclin-B-mediated G2/M arrest and targets
apoptosis through activation of caspase in mouse skin. Biochem
Biophys Res Commun. 381:253–258. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang MY, Pan H, Xu LH, Hou XF, Zha QB,
Shi ZJ, He XH and Ouyang DY: Effect of irinotecan on proliferation
and apoptosis of RAW 264.7 macrophages. Immunol J. 31:776–780.
2015.(In Chinese).
|
|
21
|
Chen J and Song WZ: Mechanism of molecular
regulation of CyclinE-CDK2. J Med Mol Biol. 3:220–222. 2006.
|
|
22
|
Shu W, Ma QJ and Ye X: CyclinE-CDK2 and
its related proteins in the cell cycle. Lett Biotechnol. 19:97–100.
2008.
|
|
23
|
O'Connell MJ, Walworth NC and Carr AM: The
G2-phase DNA-damage checkpoint. Trends Cell Biol. 10:296–303. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan XL, Xu B, Li M, Zhou Y and Cui JR:
Inhibition of diacetyldianhydrogalactitol on ornithine
decarboxylase activity and its possible mechanisms. Chin Pharm J.
44:904–908. 2009.(In Chinese).
|
